Virtual Reality (VR) is increasingly recognized as a promising tool for mental health support. Recent studies suggest that immersive environments can reduce anxiety and improve emotional regulation by promoting presence and relaxation. The biofeedback generated from VR practices has shown positive results, suggesting that calming and immersive experiences can help reduce or prevent symptoms of...
Esketamine is a novel antidepressant approved by the US Food and Drug Administration (FDA) in 2019, but comprehensive studies on the post-marketing safety evaluation of esketamine across age groups remain limited. The objective of this study is to provide the age-based pharmacovigilance profile of esketamine and the potential toxicological mechanisms, which may provide insights to inform the...
This study aims to quantitatively evaluate the efficacy and safety of various treatment regimens for treatment-resistant depression (TRD) across oral, intravenous, and intranasal routes to inform clinical guidelines. A systematic review identified randomized controlled trials on TRD, with efficacy measured by changes in the Montgomery-Åsberg Depression Rating Scale (MADRS). We developed...